Use of combined oral contraceptives alters metabolic determinants and genetic regulation of C‐reactive protein. The Cardiovascular Risk in Young Finns Study

References

• Ridker P. M., Hennekens C. H., Buring J. E., Rifai N. C‐reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–43
   PubMed Web of Science ®Google Scholar
• Danesh J., Wheeler J. G., Hirschfield G. M., Eda S., Eiriksdottir G., Rumley A., et al. C‐reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387–97
   PubMed Web of Science ®Google Scholar
• Kushner I., Rzewnicki D., Samols D. What does minor elevation of C‐reactive protein signify?. Am J Med 2006; 119: 166 e117–28
   Google Scholar
• Wilson A. M., Ryan M. C., Boyle A. J. The novel role of C‐reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol 2006; 106: 291–7
   PubMed Web of Science ®Google Scholar
• MacGregor A. J., Gallimore J. R., Spector T. D., Pepys M. B. Genetic effects on baseline values of C‐reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. Clin Chem 2004; 50: 130–4
   PubMed Web of Science ®Google Scholar
• Hage F. G., Szalai A. J. C‐reactive protein gene polymorphisms, C‐reactive protein blood levels, and cardiovascular disease risk. J Am Coll Cardiol 2007; 50: 1115–22
   PubMed Web of Science ®Google Scholar
• Carlson C. S., Aldred S. F., Lee P. K., Tracy R. P., Schwartz S. M., Rieder M., et al. Polymorphisms within the C‐reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005; 77: 64–77
   PubMed Web of Science ®Google Scholar
• Eklund C., Kivimaki M., Islam M. S., Juonala M., Kahonen M., Marniemi J., et al. C‐reactive protein genetics is associated with carotid artery compliance in men in The Cardiovascular Risk in Young Finns Study. Atherosclerosis 2008; 196: 841–8
   PubMed Web of Science ®Google Scholar
• Kivimaki M., Lawlor D. A., Smith G. D., Eklund C., Hurme M., Lehtimaki T., et al. Variants in the CRP gene as a measure of lifelong differences in average C‐reactive protein levels: the Cardiovascular Risk in Young Finns Study, 1980–2001. Am J Epidemiol 2007; 166: 760–4
   PubMed Web of Science ®Google Scholar
• Tanis B. C., van den Bosch M. A., Kemmeren J. M., Cats V. M., Helmerhorst F. M., Algra A., et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345: 1787–93
   PubMed Web of Science ®Google Scholar
• Battaglioli T., Martinelli I. Hormone therapy and thromboembolic disease. Curr Opin Hematol 2007; 14: 488–93
   PubMed Web of Science ®Google Scholar
• Raitakari M., Mansikkaniemi K., Marniemi J., Viikari J. S., Raitakari O. T. Distribution and determinants of serum high‐sensitive C‐reactive protein in a population of young adults: The Cardiovascular Risk in Young Finns Study. J Intern Med 2005; 258: 428–34
   PubMedGoogle Scholar
• Skouby S. O., Gram J., Andersen L. F., Sidelmann J., Petersen K. R., Jespersen J. Hormone replacement therapy: estrogen and progestin effects on plasma C‐reactive protein concentrations. Am J Obstet Gynecol 2002; 186: 969–77
   PubMed Web of Science ®Google Scholar
• Kluft C., Leuven J. A., Helmerhorst F. M., Krans H. M. Pro‐inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. Vascul Pharmacol 2002; 39: 149–54
   PubMedGoogle Scholar
• Buchbinder S., Kratzsch J., Fiedler G. M., Yar V., Brugel M., Leichtle A., et al. Body weight and oral contraceptives are the most important modulators of serum CRP levels. Scand J Clin Lab Invest 2008; 68: 140–4
   PubMed Web of Science ®Google Scholar
• Akerblom H. K., Viikari J., Uhari M., Rasanen L., Byckling T., Louhivuori K., et al. Atherosclerosis precursors in Finnish children and adolescents. I. General description of the cross‐sectional study of 1980, and an account of the children's and families' state of health. Acta Paediatr Scand Suppl 1985; 318: 49–63
   PubMedGoogle Scholar
• Juonala M., Viikari J. S., Hutri‐Kahonen N., Pietikainen M., Jokinen E., Taittonen L., et al. The 21‐year follow‐up of the Cardiovascular Risk in Young Finns Study: risk factor levels, secular trends and east–west difference. J Intern Med 2004; 255: 457–68
   PubMed Web of Science ®Google Scholar
• Viikari L. A., Huupponen R. K., Viikari J. S., Marniemi J., Eklund C., Hurme M., et al. Relationship between leptin and C‐reactive protein in young Finnish adults. J Clin Endocrinol Metab 2007; 92: 4753–8
   PubMedGoogle Scholar
• Telama R., Yang X., Viikari J., Valimaki I., Wanne O., Raitakari O. Physical activity from childhood to adulthood: a 21‐year tracking study. Am J Prev Med 2005; 28: 267–73
   PubMed Web of Science ®Google Scholar
• Stephens M., Smith N. J., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978–89
   PubMed Web of Science ®Google Scholar
• Sitruk‐Ware R. L., Menard J., Rad M., Burggraaf J., de Kam M. L., Tokay B. A., et al. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. Contraception 2007; 75: 430–7
   PubMed Web of Science ®Google Scholar
• Taskinen S., Kovanen P. T., Jarva H., Meri S., Pentikainen M. O. Binding of C‐reactive protein to modified low‐density‐lipoprotein particles: identification of cholesterol as a novel ligand for C‐reactive protein. Biochem J 2002; 367: 403–12
   PubMedGoogle Scholar
• Zwaka T. P., Hombach V., Torzewski J. C‐reactive protein‐mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103: 1194–7
   PubMed Web of Science ®Google Scholar
• Pasceri V., Willerson J. T., Yeh E. T. Direct proinflammatory effect of C‐reactive protein on human endothelial cells. Circulation 2000; 102: 2165–8
   PubMed Web of Science ®Google Scholar
• Verma S., Wang C. H., Li S. H., Dumont A. S., Fedak P. W., Badiwala M. V., et al. A self‐fulfilling prophecy: C‐reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913–19
   PubMed Web of Science ®Google Scholar
• Verma S., Kuliszewski M. A., Li S. H., Szmitko P. E., Zucco L., Wang C. H., et al. C‐reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C‐reactive protein and cardiovascular disease. Circulation 2004; 109: 2058–67
   PubMed Web of Science ®Google Scholar
• Godsland I. F. Biology: risk factor modification by OCs and HRT lipids and lipoproteins. Maturitas 2004; 47: 299–303
   PubMed Web of Science ®Google Scholar
• Williams M. J., Williams S. M., Milne B. J., Hancox R. J., Poulton R. Association between C‐reactive protein, metabolic cardiovascular risk factors, obesity and oral contraceptive use in young adults. Int J Obes Relat Metab Disord 2004; 28: 998–1003
   PubMedGoogle Scholar
• van Rooijen M., Hansson L. O., Frostegard J., Silveira A., Hamsten A., Bremme K. Treatment with combined oral contraceptives induces a rise in serum C‐reactive protein in the absence of a general inflammatory response. J Thromb Haemost 2006; 4: 77–82
   PubMed Web of Science ®Google Scholar
• Pradhan A. D., Manson J. E., Rossouw J. E., Siscovick D. S., Mouton C. P., Rifai N., et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. J Am Med Assoc 2002; 288: 980–7
   PubMed Web of Science ®Google Scholar
• Kelly C. C., Lyall H., Petrie J. R., Gould G. W., Connell J. M., Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86: 2453–5
   PubMed Web of Science ®Google Scholar
• Valkenburg O., Steegers‐Theunissen R. P., Smedts H. P., Dallinga‐Thie G. M., Fauser B. C., Westerveld E. H., et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case‐control study. J Clin Endocrinol Metab 2008; 93: 470–6
   PubMed Web of Science ®Google Scholar
• Banks R. E., Forbes M. A., Storr M., Higginson J., Thompson D., Raynes J., et al. The acute phase protein response in patients receiving subcutaneous IL‐6. Clin Exp Immunol 1995; 102: 217–23
   PubMed Web of Science ®Google Scholar
• Santos‐Alvarez J., Goberna R., Sanchez‐Margalet V. Human leptin stimulates proliferation and activation of human circulating monocytes. Cell Immunol 1999; 194: 6–11
   PubMed Web of Science ®Google Scholar